Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totalling 19,100 shares, a decline of 28.5% from the May 31st total of 26,700 shares. Based on an average daily trading volume, of 179,400 shares, the days-to-cover ratio is currently 0.1 days.

Enzon Pharmaceuticals Stock Performance

Shares of OTCMKTS ENZN traded down $0.01 during trading on Monday, reaching $0.17. The stock had a trading volume of 11,828 shares, compared to its average volume of 29,452. Enzon Pharmaceuticals has a fifty-two week low of $0.06 and a fifty-two week high of $0.24. The business’s 50-day moving average price is $0.13 and its 200-day moving average price is $0.10. The company has a market cap of $12.62 million, a P/E ratio of 17.00 and a beta of 0.51.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.